List view / Grid view
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal cancer.
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting…
The Agilent Seahorse XF assay platform has opened new avenues for examining mitochondrial health in a timely and effective manner.
A US study has overcome a major obstacle in cell-free DNA (cfDNA) testing or liquid biopsy, offering promising advancements in disease diagnosis and monitoring.
In this article, learn about how TMEM175 is an exciting new target in normal physiology and in disease. Also, read about how the use of biomarkers in Alzheimer’s drug development will address many of the challenges currently encountered.
In the unmet need for effective treatments to alleviate suffering and prevent premature death across the spectrum of genetic diseases, Brent Warner, Poseida Therapeutics, shares that the ability to edit DNA holds hope for patients currently experiencing incurable genetic diseases and has spurred ongoing efforts to develop and improve gene…
US researchers find that recurrent bouts of systemic lupus erythematosus is closely tracked with measurable upticks in growth in the gut of a certain species of bacteria.
Download your FREE ebook, featuring articles about cancer therapies, immune system breakthroughs, therapeutic genetic engineering, and advancements in gene editing.
According to Swedish study, muscle fibres found in extraocular muscles seem to be resistant and even increase in proportion in those with ALS. This offers new treatment avenues for slowing down the disease.
In this article, Dr Vincent Blomen, Senior Director of Target Discovery at Scenic Biotech, takes us through the realm of rare diseases. In the case of most of these diseases, a singular genetic anomaly often reigns supreme, yet its impact on patients can be vastly divergent. Enter modifier genes, the…
A study out of South Korea outlines the potential of an AI-based imaging tool for diagnosing and analysing cardiac disease.
14 June 2023 | By Sartorius
Watch our virtual panel, where you'll uncover the game-changing advantages of organoids over traditional 2D cultures. Our experts will explore the immense potential of organoids in oncology and immuno-oncology research.
Fresh insights from University of Edinburgh into a protein that causes damage in kidneys and hearts could open up new treatment options for chronic kidney disease.
US researchers use genome sequencing to reveal genetic basis for disabling pansclerotic morphea, a severe inflammatory disease.
Scientists have discovered that a vaccinated San Diego resident has produced antibodies that are effective against multiple variants of SARS-CoV-2, including Omicron. The research also identified three antibodies that can neutralise the virus, giving new insights into different binding mechanisms with the SARS-CoV-2 spike protein. The findings could help to…
